ArticleCommunications medicine2026
Complement factor B deficiency promotes lung cancer progression via FOS-mediated tryptophan metabolism and immune suppression.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComplement Factor B (CFB) is a component of the alternative complement pathway with emerging roles in cancer biology. This study investigated the role of CFB in lung cancer progression and characterized its downstream molecular and immunological effects.
methodsWe performed transcriptomic analysis of CFB-silenced lung adenocarcinoma cells and validated findings in clinical specimens. CFB deficiency was assessed using in vitro functional assays, metabolite measurements, and T cell coculture systems. Immunomodulatory effects were evaluated in vivo using tumor models treated with an indoleamine 2,3-dioxygenase (IDO) inhibitor.
resultsCFB silencing activates a proto-oncogene C-Fos (FOS)-dependent upregulation of tryptophan metabolism enzymes. CFB expression inversely correlates with FOS and tryptophan metabolic enzymes in human lung cancer specimens, with stronger alterations in advanced disease. Mechanistically, CFB deficiency enhances tryptophan catabolism to kynurenine, promoting regulatory T cell activation through aryl hydrocarbon receptor (AhR) signaling while suppressing CD8 + T cell function. In vivo, CFB-knockdown tumors show accelerated growth, enhanced immune suppression, and increased tryptophan catabolism. These effects are reversed by IDO inhibitor treatment.
conclusionWe identify a CFB-FOS-IDO axis that regulates tryptophan metabolism and shapes the tumor immune microenvironment in lung cancer. CFB deficiency promotes tumor progression by enhancing tryptophan catabolism, resulting in an immunosuppressive microenvironment. These findings reveal potential therapeutic targets to overcome immune evasion in lung cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.